Ubrogepant (Ubrelvy™) is an orally administered, small molecule, highly-selective,
calcitonin gene-related peptide (CGRP) antagonist that was developed by Allergan under …

Both rimegepant and ubrogepant have published positive randomized placebo-controlled
clinical trials data. Vazegepant is the first intranasal gepant for the acute treatment of …

Purpose Current acute migraine treatment consists of migraine-specific agents, namely
triptans, as well as non-specific analgesia, such as non-steroidal anti-inflammatory drugs …

Small molecule calcitonin gene-related peptide (CGRP) receptor antagonists are commonly
referred to as gepants. The first generation of gepants provided the first line of evidence of …

Migraine is the primary headache disorder affecting a significant population worldwide.
Ubrogepant is an orally bioavailable calcitonin gene-related peptide (CGRP) receptor …

Purpose In four large controlled trials with lasmiditan and ubrogepant placebo was
administered in the first step to demonstrate an effect on migraine attack. In the same trials …